Relapsed/Refractory B-Cell LymphomaPhase 1/2NCT03223610Papers
ViPOR Combination
Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma
Preliminary Safety and Tolerability of CD19x22 CAR T Cells in Adolescent and Adult R/R B-NHL Patients
What the film says
CAR T cells aimed at a marker called CD19 can cure lymphomas nothing else touched. But they fail in more than half of patients, and one escape is simple: the lymphoma stops making CD19, and the cells lose sight of it.
The idea: give the cells two ways to see the cancer.
A patient's own T cells receive one gene that builds two receptors, for CD19 and for CD22, a second protein on the same cells. Lose one marker and the cell is still caught. The cells are infused once.
Colorado's trial, with Manali Kamdar, includes people whose lymphoma returned after earlier CAR T cells, and a group with lymphoma in the brain, where little works. First question: safety. Public record; not medical advice.
Sources behind this film
Neelapu SS. N Engl J Med, 2017
CD19 CAR T cures some lymphomas; fails in more than half; CD19 loss is a common escape
Spiegel JY. Nat Med, 2021
CD19 CAR T cures some lymphomas; fails in more than half; CD19 loss is a common escape
Single (bicistronic) vector encoding CD19 and CD22 receptors; Lymphodepletion then one infusion; cohorts include prior CAR T recipients and primary/secondary CNS lymphoma; Manali Kamdar, University of Colorado Hospital
The drug
Autologous peripheral blood mononuclear cells transduced with CD19x22 CAR T lentiviral vector.
To determine the safety and tolerability of infusing CD19x22 CAR T, generated using a bicistronic vector, in adolescents and adults with R/R B-NHL, and to determine the recommended Phase II dose (RP2D). Secondary objectives for all subjects include: 1) Feasibility of manufacturing and infusion, 2) Safety of infusion and 3) Efficacy: Descriptive characterization of complete response (CR), partial response (PR), stable disease (SD), and progressive disease (PD) at Day +90.
As well, progression-free survival (PFS), overall survival (OS), duration of remission (DOR) and overall response rate (ORR) will be determined at 1 year. Efficacy will be descriptively stratified based on prior receipt of CAR-T cell therapy.
The study
This open-label, single arm phase 1 trial aims to determine the safety and tolerability of anti-CD19 and anti-CD22 chimeric antigen receptor-expressing (CAR) T cells (CD19x22 CAR T) in adolescents and adults with relapsed/refractory (R/R) B-cell Non-Hodgkin Lymphoma (B-NHL). This trial will determine the maximum tolerated dose of CD19x22 CAR T cells using a standard 3+3 trial design.
Eligibility
Inclusion criteria as written on the registry, trimmed. The full list, with exclusions, is on the live record.
For you, or someone you love
A complex diagnosis brings new questions every week, in a trial and out of one. Triangle keeps your whole medical file together, reads it with you in plain language, and helps you and your family decide what to ask next.
Then $9 a month. Cancel anytime.
Requested from your hospitals and clinics through the national networks. Add scans, pathology and anything on paper.
Reports explained as they come in, with lab values you can follow before treatment, during a trial and after.
Ask about your own file, and walk in with questions for your oncologist or the trial team.
Share one profile with the family helping you, and with your doctors.
Members also get a deeper analysis of their records and any sequencing data, including clinical trials that may fit, reviewed by a licensed physician before they receive it.
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.
How these trials work: what Phase 1 actually is · common questions Not clinical evidence.